Frontiers in Immunology · 2022 · 11 citations · 9 references
Life SciencesImmunologyOncologyCancer ImmunologyClinical ImmunologyImmunotherapyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune CheckpointsImmune-related Adverse EventsImmuno-oncology BiomarkersCd4 Positive T CellsCd8 Positive T CellsDrug Receptor OccupancyFlow Cytometry ImmunophenotypingImmune Checkpoint Inhibitor BiomarkersImmune-mediated Adverse EventsReceptor Occupancy AnalysisReceptor Occupancy Measurement
Immune checkpoint inhibitors (ICI) widely improved the treatment of solid and hematologic malignancies. Yet, a remarkable proportion of patients receiving ICI develop immune related adverse events (irAEs) which are difficult to define as treatment-related. This underlines the need to develop a biomarker to guide irAE diagnosis. We developed a novel flow cytometry assay combining measurement of anti-PD-1 (programmed cell death protein-1) occupancy and evaluation of remaining PD-1 receptor availability with anti-IgG4 PE and anti-PD-1 BV421. We prospectively collected blood and biological fluids samples from patients treated by IgG4 anti-PD-1 therapy (nivolumab or pembrolizumab), with (n=18) or without (n=12) current irAE. We analyzed PD-1+ and IgG4+ staining pattern and MFI values of these parameters on CD4 and CD8 T cells, and IgG4+/PD-1+ MFI ratios are calculated. A higher mean fluorescence intensity IgG4+/PD-1+ ratio was measured on peripheral CD4+ T cells of irAE cases, when compared to controls (p=0.003). ICI-related toxicity is therefore associated with increased therapeutic antibody occupancy of PD-1 receptors on CD4+ T cells. Furthermore, in one case of ICI-related pneumonitis, binding of therapeutic antibody was stronger on lung CD4+ T cell than in blood. In another case of ICI-related encephalitis, the PD-1 receptor occupancy was total on CSF CD4 T cells, but only partial on peripherical CD4 T cells. Our results suggest that flow cytometry monitoring of ICI occupancy can be used in patients treated with monoclonal ICI to guide irAE diagnosis.
9
Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider et al. · Journal of Clinical Oncology · 2018 · 3.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. Johnson, Justin M. Balko, Margaret Compton et al. · New England Journal of Medicine · 2016 · 2.3K citations · Full text
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
Adrienne Luoma, Shengbao Suo, Hannah L. Williams et al. · Cell · 2020 · 480 citations · Full text
Medicine, Immunology, Oncology +16
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
Mehdi Touat, Thierry Maisonobe, Omar Ben Hadj Salem et al. · Neurology · 2018 · 330 citations
Life Sciences, Immunology, Pathology +17